24 January 2012 - US cancer therapies developer Blueprint Medicines said today it had appointed Christoph Lengauer as its chief scientific officer.

Lengauer most recently served as vice president and global head of oncology drug discovery and preclinical development at Sanofi (EPA:SAN).
 

 

 

You must be logged in to view the whole article.
Click here if you require signing up